![]() ![]() To prevent clinicians from providing different treatment for intervention and control groups, and to prevent them from reflecting their views on the allocation to the participants. To ensure the data analysis is not influenced during or after the trial until analyses are complete for example, by conscious or unconscious selection of statistical tests and reporting. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. In a trial of treatments for multiple sclerosis, when blinded neurologists performed disease assessment, there was no difference between intervention and placebo, but when unblinded neurologists performed the assessment, there was an apparent benefit of the intervention over the control treatment. Outcomes could be assessed differently if the assessors know which participant was receiving which intervention. Study staff collecting data might record differently for different participants if they know which group they are in. Blinding in randomised trials: hiding who got what. They also might be more likely to be lost to follow-up. A participant who knows they are receiving the placebo might be disappointed: they might attend more doctor’s appointments in order to try to get additional treatment. To ensure participants don’t change their behaviour as a result of knowing what their group assignment is and do not report their subjective outcome measures differently as a result. ![]() Blinding in a trial can be single, double-blind or triple blind, however, what is important is defining who was blinded as blinding terms are often easily confused. The aim of blinding is to reduce bias due to the knowledge of which intervention or control is being received by study participants.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |